A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
← catalyst calendarNCT06419205 · readout ≤ 559 d
Sponsored by Akebia Therapeutics (industry) · AKBA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Sites
2
Countries
Brazil, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-30 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- IgA Nephropathy
- Lupus Nephritis (LN)
- C3 (Complement Component 3) Glomerulopathy
Intervention
- Drug: ADX-097
Primary outcome
what the primary-completion date above is the date OFNumber of participants reporting treatment emergent adverse events (TEAEs)
measured Up to 30 weeks
Permalink · AKBA's whole pipeline · Catalyst calendar · Every registered study · What changed